Arcturus Therapeutics (NASDAQ:ARCT) Issues Quarterly Earnings Results

Arcturus Therapeutics (NASDAQ:ARCT) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.58, Zacks reports. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.

Arcturus Therapeutics Stock Up 5.6%

NASDAQ:ARCT traded up $0.61 on Monday, reaching $11.59. The stock had a trading volume of 687,095 shares, compared to its average volume of 450,190. The stock has a fifty day moving average price of $11.87 and a 200-day moving average price of $15.43. Arcturus Therapeutics has a 1-year low of $8.04 and a 1-year high of $45.00. The company has a market capitalization of $314.33 million, a P/E ratio of -5.22 and a beta of 2.36.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ARCT. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. BTIG Research set a $48.00 price target on Arcturus Therapeutics and gave the company a “buy” rating in a report on Monday, March 10th. Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Finally, Canaccord Genuity Group reduced their price target on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $59.20.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.